CL2020003131A1 - Compuestos de purinona y su uso en el tratamiento del cáncer - Google Patents

Compuestos de purinona y su uso en el tratamiento del cáncer

Info

Publication number
CL2020003131A1
CL2020003131A1 CL2020003131A CL2020003131A CL2020003131A1 CL 2020003131 A1 CL2020003131 A1 CL 2020003131A1 CL 2020003131 A CL2020003131 A CL 2020003131A CL 2020003131 A CL2020003131 A CL 2020003131A CL 2020003131 A1 CL2020003131 A1 CL 2020003131A1
Authority
CL
Chile
Prior art keywords
compounds
salts
cancer
treatment
methods
Prior art date
Application number
CL2020003131A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Frederick Woolf Goldberg
Attilla Kuan Tsuei Ting
Martin Richard Howard
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CL2020003131A1 publication Critical patent/CL2020003131A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measurement Of Radiation (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I):<br /> y sales farmacéuticamente aceptables de los mismos, donde R1, A1, A2 y A3 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para <br /> tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.
CL2020003131A 2018-06-15 2020-12-02 Compuestos de purinona y su uso en el tratamiento del cáncer CL2020003131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
CL2020003131A1 true CL2020003131A1 (es) 2021-04-30

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003131A CL2020003131A1 (es) 2018-06-15 2020-12-02 Compuestos de purinona y su uso en el tratamiento del cáncer

Country Status (29)

Country Link
US (2) US11884671B2 (es)
EP (1) EP3807278B1 (es)
JP (1) JP7472044B2 (es)
KR (1) KR102793666B1 (es)
CN (1) CN112236431B (es)
AR (1) AR114971A1 (es)
AU (1) AU2019287295B2 (es)
BR (1) BR112020025127A2 (es)
CA (1) CA3102195A1 (es)
CL (1) CL2020003131A1 (es)
CO (1) CO2020015758A2 (es)
CR (1) CR20200620A (es)
DO (1) DOP2020000241A (es)
EA (1) EA202190006A1 (es)
EC (1) ECSP20080276A (es)
ES (1) ES2931448T3 (es)
IL (1) IL279370B2 (es)
JO (1) JOP20200315B1 (es)
MA (1) MA52886A (es)
MX (1) MX2020013570A (es)
NI (1) NI202000099A (es)
PE (1) PE20210003A1 (es)
PH (1) PH12020552148A1 (es)
SG (1) SG11202012035WA (es)
TW (1) TWI820146B (es)
UA (1) UA126837C2 (es)
UY (1) UY38263A (es)
WO (1) WO2019238929A1 (es)
ZA (1) ZA202100195B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
CN114728969B (zh) * 2019-11-25 2024-03-08 再鼎医药(上海)有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物
WO2021136463A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
WO2021204111A1 (zh) * 2020-04-10 2021-10-14 南京明德新药研发有限公司 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
CN114315834B (zh) * 2020-04-17 2024-01-05 成都百裕制药股份有限公司 咪唑啉酮衍生物及其在医药上的应用
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CA3192868A1 (en) * 2020-09-24 2022-03-31 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117377676A (zh) * 2021-06-29 2024-01-09 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物
WO2023036156A1 (zh) * 2021-09-07 2023-03-16 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025199376A1 (en) * 2024-03-22 2025-09-25 Padarn Therapeutics, Inc. Cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536841A (ja) * 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
WO2010118207A1 (en) * 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
PL2493895T3 (pl) * 2009-10-29 2017-10-31 Vectura Ltd Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
MX2013010439A (es) * 2011-03-11 2014-07-09 Gilead Calistoga Llc Tratamientos combinados para neoplasias hematologicas.
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
PE20191474A1 (es) * 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
JOP20200315B1 (ar) 2024-04-18
EA202190006A1 (ru) 2021-03-29
MA52886A (fr) 2021-04-21
ES2931448T3 (es) 2022-12-29
AR114971A1 (es) 2020-11-11
IL279370A (en) 2021-01-31
KR102793666B1 (ko) 2025-04-08
US20240150355A1 (en) 2024-05-09
CO2020015758A2 (es) 2021-04-30
CR20200620A (es) 2021-03-09
EP3807278A1 (en) 2021-04-21
WO2019238929A1 (en) 2019-12-19
NZ771886A (en) 2024-07-26
ECSP20080276A (es) 2021-01-29
EP3807278B1 (en) 2022-08-31
NI202000099A (es) 2021-09-24
UA126837C2 (uk) 2023-02-08
AU2019287295B2 (en) 2022-05-26
UY38263A (es) 2019-12-31
CN112236431A (zh) 2021-01-15
PE20210003A1 (es) 2021-01-05
JOP20200315A1 (ar) 2020-12-07
CN112236431B (zh) 2024-02-13
TWI820146B (zh) 2023-11-01
SG11202012035WA (en) 2021-01-28
PH12020552148A1 (en) 2021-07-05
IL279370B1 (en) 2024-07-01
CA3102195A1 (en) 2019-12-19
ZA202100195B (en) 2022-08-31
KR20210020944A (ko) 2021-02-24
US20210171525A1 (en) 2021-06-10
IL279370B2 (en) 2024-11-01
JP2021527095A (ja) 2021-10-11
AU2019287295A1 (en) 2021-02-04
MX2020013570A (es) 2021-05-27
US11884671B2 (en) 2024-01-30
JP7472044B2 (ja) 2024-04-22
DOP2020000241A (es) 2021-04-30
BR112020025127A2 (pt) 2021-03-23
TW202035410A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
CL2020003131A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX389244B (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer